A small peptide (CEL-1000) derived from the β-chain of the human major histocompatibility complex class II molecule induces complete protection against malaria in an antigen-independent manner

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 7, 2004, Pages 2455-2463

  Charoenvit, Yupin ^a   Brice, Gary T ^a   Bacon, David ^a   Majam, Victoria ^a,c   Williams, Jackie ^b   Abot, Esteban ^a,c   Ganeshan, Harini ^a,c   Sedegah, Martha ^a   Doolan, Denise L ^a,d   Carucci, Daniel J ^a   Zimmerman, Daniel H ^e  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e CEL SCI Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; CEL 1000; GAMMA INTERFERON; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE DERIVATIVE; RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; BETA CHAIN; BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; MALARIA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PLASMODIUM; PRIORITY JOURNAL; SPLEEN; SPOROZOITE; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODY SPECIFICITY; ANTIGENS, PROTOZOAN; ANTIMALARIALS; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENES, MHC CLASS II; INTERFERON TYPE II; KINETICS; LIVER; MALARIA; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PLASMODIUM BERGHEI; PLASMODIUM YOELII; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA;

EID: 3042619328     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.7.2455-2463.2004     Document Type: Article

References (27)

1. 1 lupus-prone mice and the Leishmania major-susceptible BALB/c strain. J. Immunol. 161:6878-6884.
2. Cammarota, G., A. Scheirle, B. Takacs, D. M. Doran, R. Knorr, W. Bannwarth, J. Guardiola, and F. Sinigaglia. 1992. Identification of a CD4 binding site on the β-2 domain of HLA-DR molecule. Nature 356:799-801.
3. + T-cell- and gamma interferon-dependent protection against murine malaria by immunization with linear synthetic peptides from a Plasmodium yoelii 17-kilodalton hepatocyte erythrocyte protein. Infect. Immun. 67:5604-5614.
4. + T cell-, interferon β-, and nitric oxide-dependent immunity. J. Exp. Med. 183:1739-1746.
5. Goel, N., D. H. Zimmerman, and K. S. Rosenthal. 2003. Heteroconjugate vaccine containing a T cell epitope from HSV-1 glycoprotein C elicits the Th1 responses and protection. Vaccine 21:4410-4420.
6. Gorham, J. D., M. L. Guler, D. Fenoglio, U. Gubler, and K. M. Murphy. 1998. Low dose TGF-β attenuates IL-12 responsiveness in murine Th cells. J. Immunol. 161:1664-1670.
7. Gorham, J. D., M. L. Guler, R. G. Steen, A. J. Mackey, M. J. Daly, K. Frederick, W. F. Dietrich, and K. M. Murphy. 1996. Genetic mapping of a murine locus controlling development of T helper 1/T helper 2 type responses. Proc. Natl. Acad. Sci. USA 93:12467-12472.
8. Himmelrich, H., P. Launois, I. Maillard, T. Biedermann, F. Tacchini-Cottier, R. M. Locksley, M. Rocken, and J. A. Louis. 2000. In BALB/c mice, IL-4 production during the initial phase of infection with Leishmania major is necessary and sufficient to instruct Th2 cell development resulting in progressive disease. J. Immunol. 164:4819-4852.
9. Konig, R., L. Y. Huang, and R. N. Germain. 1992. MHC class II interaction with CD4 mediated by a region analogous to the MHC class I binding site for CD8. Nature 356:796-798.
10. Liu, J., and D. Beller. 2002. Aberrant production of IL-12 by macrophages from several autoimmune-prone mouse strains is characterized by intrinsic and unique patterns of NF-kappa B expression and binding to the IL-12 p40 promoter. J. Immunol. 169:581-586.
11. Mellouk, S., S. J. Green, C. A. Nacy, and S. L. Hoffman. 1991. INF-γ inhibits development of Plasmodium berghei exoerythrocytic stages in hepatocytes by an L-arginine-dependent effector mechanism. J. Immunol. 146:3971-3976.
12. Mellouk, S., S. L. Hoffman, Z. Z. Liu, P. de la Vega, T. R. Billiar, and A. K. Nussler. 1994. Nitric oxide-mediated anti-plasmodial activity in human and murine hepatocytes induced by γ-interferon and the parasite itself: enhancement by exogenous tetrahydrobiopterin. Infect. Immun. 62:4043-4046.
13. Menon, J. N., and P. A. Bretscher. 1996. Characterization of the immunological memory state generated in mice susceptible to Leishmania major following exposure to low dose of L. major and resulting to a normally pathogenic challenge. Eur. J. Immunol. 26:243-249.
14. Menon, J. N., and P. A. Bretscher. 1998. Parasite dose determines the Th1/Th2 nature of the response to Leishmania major independently of infection route and strain of host parasite. Eur. J. Immunol. 28:4024-4028.
15. National Research Council, Institute of Laboratory Animal Resources. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, D.C.
16. Nishikomori, R., S. Gurunathan., K. Nishikomuri, and W. Strober. 2001. BALB/c mice bearing a transgenic IL-12 receptor β2 gene exhibit a nonhealing phenotype to Leishmania major infection despite intact IL-12 signaling. J. Immunol. 166:6776-6783.
17. Pacheco, N. D., C. P. Strome, F. Mitchell, M. P. Bawden, and R. L. Beaudoin. 1979. Rapid, large-scale isolation of Plasmodium berghei sporozoites from infected mosquitoes. J. Parasitol. 65:414-417.
18. Parham, P., M. J. Androlewicz, N. J. Holmes, and B. E. Rothenberg. 1983. Arginine 45 is a major part of the antigenic determinant of human β2-microglobulin recognized by mouse monoclonal antibody BBM.1. J. Biol. Chem. 258:6179-6186.
19. Richie, T. L., and A. Saul. 2002. Progress and challenges for malaria vaccines. Nature 415:694-701.
20. Rosenthal, K. S., H. Mao, W. I. Horne, C. Wright, and D. Zimmerman. 1999. Immunization with a LEAPS™ heteroconjugate containing a CTL epitope and a peptide from beta-2-microglobulin elicits a protective and DTH response to herpes simplex virus type 1. Vaccine 17:535-542.
21. Sedegah, M., R. Hedstrom, P. Hobart, and S. L. Hoffman. 1999. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc. Natl. Acad. Sci. USA 91:9866-9870.
22. + T cells. J. Exp. Med. 180:353-358.
23. + T cell and IFN-γ-dependent elimination of infected hepatocytes. J. Immunol. 157:4061-4067.
24. + T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc. Natl. Acad. Sci. USA 85:573-576.
25. Witney, A. A., D. L. Doolan, R. M. Anthony, W. R. Weiss, S. L. Hoffman, and D. J. Carucci. 2001. Determining liver stage parasite burden by real time quantitative PCR as a method for evaluating pre-erythrocytic malaria vaccine efficacy. Mol. Biochem. Parasitol. 118:223-245.
26. Zimmerman, D., S. Morris, D. Rouse, K. Worthington, D. Elliott, and K. Rosenthal. 1996. Immunization with peptide heteroconjugates primes a T helper cell type 1-associated antibody (IgG2a) response that recognizes the native epitope on the 38-kDa protein of Mycobacterium tuberculosis. Vaccine Res. 5:103-118.
27. SF2 p17) and peptide segments of human β-2-microglobulin or MHC II β chain. Vaccine 19:4750-4759.